What is the endocannabinoid system and what is its role?Nick JikomesDecember 12, 2016
Our endocannabinoid system (ECS) does just that. But it isn’t there just to allow us to enjoy the effects of our favorite strain. It serves a vital purpose for our health and well-being because it regulates key aspects of our biology.
So, what’s it doing, and how does it work?
What is the endocannabinoid system and what does it do?
The endocannabinoid system (ECS) is a biological system first discovered in the late ’80s and early ’90s, although much remains unknown about the system today.
The ECS is largely comprised of endocannabinoids, receptors, and enzymes that are believed to help regulate a variety of functions in human including sleep, mood, memory, appetite, reproduction, and pain sensation. Scientists still have plenty of questions about the human endocannabinoid system and how it functions.
Homeostasis: Staying in the Goldilocks zone
To understand the human endocannabinoid system, it’s helpful to know a little about one of the most fundamental concepts in biology: homeostasis. And the best way to understand homeostasis is to think of Goldilocks and the Three Bears.
The classic fairy tale illustrates the idea that the best outcome often lies somewhere in the middle, between two extremes. We don’t want things too hot or too cold, but just right.
Homeostasis is the concept that most biological systems are actively regulated to maintain conditions within a narrow range. Our bodies don’t want temperature to be too hot or too cold, blood sugar levels too high or too low, and so on. Conditions need to be just right for our cells to maintain optimum performance, and exquisite mechanisms have evolved to draw them back to the Goldilocks zone if they move out.
The body’s endocannabinoid system (ECS) is a vital molecular system for helping maintain homeostasis—it helps cells stay in their Goldilocks zone.
Key pieces of the endocannabinoid system (ECS)
Because of its crucial role in homeostasis, the ECS is widespread throughout the animal kingdom. Its key pieces evolved a long time ago, and the ECS can be found in all vertebrate species.
The three key components of the human endocannabinoid system are:
- Cannabinoid receptors found on the surface of cells
- Endocannabinoids, small molecules that activate cannabinoid receptors
- Metabolic enzymes that break down endocannabinoids after they are used
Why do we have cannabinoid receptors and what are they?
Cannabinoid receptors sit on the surface of cells and “listen” to conditions outside the cell. They transmit information about changing conditions to the inside of the cell, kick-starting the appropriate cellular response.
There are two major cannabinoid receptors: CB1 and CB2. These aren’t the only cannabinoid receptors, but they were the first ones discovered and remain the best-studied.
CB1 receptors are one of the most abundant receptor types in the brain. These are the receptors that interact with THC to get people high.
CB2 receptors are more abundant outside of the nervous system, in places like the immune system. However, both receptors can be found throughout the body (Figure 1).
What are endocannabinoids?
Endocannabinoids are molecules that, like the plant cannabinoid THC, bind to and activate cannabinoid receptors. However, unlike THC, endocannabinoids are produced naturally by cells in the human body (“endo” means “within,” as in within the body).
There are two major endocannabinoids: anandamide and 2-AG (Figure 2). These endocannabinoids are made from fat-like molecules within cell membranes, and are synthesized on-demand. This means that they get made and used exactly when they’re needed, rather than packaged and stored for later use like many other biological molecules.
Anandamide. Derived from the Sanskrit word “ananda,” which translates to “joy,” “bliss,” or “delight,” anandamide is sometimes called “the bliss molecule.” More scientifically known as N-arachidonoylethanolamine (AEA), this fatty acid neurotransmitter is the subject of several scientific studies that try to determine its effects on humans. First identified and named in 1992 by Raphael Mechoulam, anandamide is believed to have an impact on working memory and early stage embryo development.
2-AG. 2-ArachidonoylGlycerol (2-AG) was first described in 1994-1995 by Raphael Mechoulam and his student Shimon Ben-Shabat. While it was previously a known chemical compound, this is when scientists first became aware of its affinity for cannabinoid receptors. Present at high levels in the central nervous system, 2-ArachidonoylGlycerol (2-AG) has been identified in maternal bovine as well as human milk.
The third piece of the endocannabinoid triad includes the metabolic enzymes that quickly destroy endocannabinoids within the ECS once they are used. The two big enzymes are FAAH, which breaks down anandamide, and MAGL, which breaks down 2-AG (Figure 3).
These enzymes ensure that endocannabinoids get used when they’re needed, but not for longer than necessary. This process distinguishes endocannabinoids from many other molecular signals in the body, such as hormones or classical neurotransmitters, which can persist for many seconds or minutes, or get packaged and stored for later use.
These three key components of the endocannabinoid system can be found within almost every major system of the body. When something brings a cell out of its Goldilocks zone, these three pillars of the ECS are often called upon to bring things back, thus maintaining homeostasis.
Because of its role in helping bring things back to their physiological Goldilocks zone, the ECS is often engaged only when and where it’s needed. Dr. Vincenzo Di Marzo, Research Director at the Institute of Biomolecular Chemistry in Italy, put it to us this way:
“With the ‘pro-homeostatic action of the ECS’ we mean that this system of chemical signals gets temporarily activated following deviations from cellular homeostasis. When such deviations are non-physiological, the temporarily activated ECS attempts, in a space- and time-selective manner, to restore the previous physiological situation (homeostasis).”
In other words, the endocannabinoid system helps bring things back to the biological Goldilocks zone.
Below we will consider examples of how the ECS helps maintain homeostasis in two areas: the firing of brain cells in the nervous system and the inflammatory response of the immune system.
Endocannabinoid regulation of brain cell firing
Brain cells (neurons) communicate by sending electrochemical signals to each other. Each neuron must listen to its partners to decide whether it will fire off its own signal at any given moment. However, neurons don’t like to get too much input—there’s a Goldilocks zone. If they get overloaded by signals, it can be toxic.
That’s where endocannabinoids come in.
Consider a simplified scenario with one neuron listening to two others.
One of the two outputting neurons might become overactive and send too many signals to the neuron that’s listening. When that happens, the neuron that’s listening will make endocannabinoids specifically where it’s connected to the overactive neuron. Those endocannabinoids will travel back to the “loud” neuron where they bind to CB1 receptors, transmitting a signal that instructs it to quiet down. This brings things back to the Goldilocks zone, maintaining homeostasis (Figure 4).
As the example above illustrates, endocannabinoids travel backward, which is why they’re known as retrograde signals. Most of the time, information flow between neurons is strictly in one direction, from sender neurons that release neurotransmitter signals to receiver neurons that listen to those signals. Endocannabinoids allow receiver neurons to regulate how much input they’re getting, and they do this by sending retrograde signals (endocannabinoids) back to overactive sender neurons.
But the brain isn’t the only organ that needs to maintain homeostasis. Every other system of the body, the digestive, immune, ECS system, etc., needs to carefully regulate how its cells are functioning. Proper regulation is crucial for ensuring survival.
Endocannabinoid regulation of inflammation
Inflammation is a natural protective reaction the immune system has in response to infection or physical damage. The purpose of inflammation is to remove pathogens (germs) or damaged tissue. The inflamed area is produced by fluid and immune cells moving into the area to do the dirty work and return things to their Goldilocks zone.
It’s important that inflammation be limited to the location of damage and doesn’t persist longer than needed, which can cause harm. Chronic inflammation and autoimmune diseases are examples of the immune system getting activated inappropriately. When that happens, the inflammatory response lasts too long, which results in chronic inflammation, or gets directed toward healthy cells, which is known as autoimmunity.
In general, endocannabinoids seem to suppress or limit the immune system’s inflammatory signals. Professor Prakash Nagarkatti, Vice President for Research at the University of South Carolina whose laboratory studies endocannabinoid regulation of immune responses, told us how tweaking the endocannabinoid system might be a good way to treat inflammatory diseases.
“Most of our research demonstrates that endocannabinoids are produced upon activation of immune cells and may help regulate the immune response by acting as anti-inflammatory agents. Thus, interventions that manipulate the metabolism or production of endocannabinoids may serve as a novel treatment modality against a wide range of inflammatory disease.”
Consider a normal immune response triggered by a bacterial infection. First, immune cells detect the presence of bacteria and release pro-inflammatory molecules that tell other immune cells to come and join the fight.
Endocannabinoids get released as well (Figure 4), which also signal to other immune cells for assistance and likely help limit the inflammatory response so it isn’t excessive. By tightly regulating inflammation, the immune system can destroy germs or remove damaged tissue, and then stop. This prevents excessive inflammation, allowing cells, and thus the body, to return to the Goldilocks zone.
Other treatment potential of cannabinoids
While much remains to be discovered about the endocannabinoid system and the various medical uses and treatment potential of cannabinoids, certain conditions have been identified as key areas of research potential. In particular, cannabinoids may be used to treat:
- Acute and chronic kidney disease
- Alzheimer’s disease
- Autoimmune diseases
- Cardiovascular disease
- Chronic pain conditions
With increased research, this list is likely to grow significantly.
How do plant cannabinoids like THC and CBD interact with the endocannabinoid system?
The reason that plant cannabinoids have psychoactive and medicinal effects within the body is, in large part, because we have an endocannabinoid system (ECS) that they can interact with. For example, THC gets you high because it activates the CB1 receptor within the brain. Endocannabinoids like anandamide also activate CB1.
So why aren’t we constantly high?
A couple big reasons. First, THC doesn’t interact with CB1 receptors in exactly the same fashion as the body’s natural endocannabinoids. Second, the metabolic enzymes that quickly break down endocannabinoids like anandamide don’t work on THC, so THC lingers around for much longer.
It’s important to remember that molecules like cannabinoids and other neurotransmitters rarely interact with only one receptor type; they often interact with many. The plant-based cannabinoid CBD illustrates this nicely, as it interacts with numerous receptor types in the brain.
So while plant cannabinoids may activate the same cannabinoid receptors as endocannabinoids, they will likely interact with several other receptors and therefore have distinct effects.
CBD is also interesting because it can affect overall levels of endocannabinoids in the brain, referred to as “endocannabinoid tone.” CBD inhibits the FAAH enzyme, which breaks down anandamide. Thus, CBD can increase anandamide levels by preventing FAAH from breaking it down. Inhibiting the FAAH enzyme has been shown to be a useful strategy for treating anxiety disorders, and some of CBD’s anti-anxiety properties may come from its ability to inhibit this enzyme and thereby increase endocannabinoid tone.
Endocannabinoid system summary
The endocannabinoid system (ECS), comprised of cannabinoid receptors, endocannabinoid molecules, and their metabolic enzymes, is a crucial molecular system that the body uses to help maintain homeostasis. Because of its vital role in making sure that cells and systems remain in their physiological Goldilocks zone, the ECS is tightly regulated; it gets deployed exactly when and where it’s needed. However, this doesn’t mean that activating the ECS, through consumption of cannabis or by any other means, will always make things just right.
Like any other complex biological system, the ECS can go awry. “If deviation from physiological homeostasis is prolonged, due to either external factors or chronic pathological conditions, the ECS can lose its time- and space-selective mode of action and start affecting inappropriate cells,” Dr. Di Marzo explained. “In these cases, the ECS, instead of being beneficial, may actually contribute to disease progression.”
It’s important to remember that activating the ECS, through cannabis consumption or by any other means, isn’t a cure-all. Like most of biology, it’s complicated.
By understanding the biological Goldilocks principle (homeostasis), and how the ECS illustrates this at the cellular level, we can more deeply appreciate why we have an ECS to begin with, and how a variety of cannabis-based therapies might actually work. The presence and critical function of the ECS across many systems of the body, including the nervous and immune systems, explains why such a wide variety of ailments and disease states are responsive to cannabis-based interventions.
- Gunduz-cinar O, Hill MN, Mcewen BS, Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci. 2013;34(11):637-44. [PDF]
- Ligresti A, De petrocellis L, Di marzo V. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiol Rev. 2016;96(4):1593-659. [PDF]
- Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333-49. [PDF]
- Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. [PDF]
- Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678-82. [PDF]
- Zlebnik NE, Cheer JF. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? Annu Rev Neurosci. 2016;39:1-17. [PDF]